A new white paper from the Network for Excellence in Health Innovation encourages the use of outcomes-based contracting for novel oncology drugs.
Smita Jaggernauth, PharmD
Advertisement
Articles by Smita Jaggernauth, PharmD
A specific mutation has been linked with acquired resistance in immunotherapy drugs used to treat non–small lung cancer (NSCLC).
Advertisement
Latest Updated Articles
Mutation May Be Associated With Resistance to NSCLC ImmunotherapyNovember 8th 2017
Advertisement
Advertisement
Trending on AJMC
1
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
2
FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance
3
Respiratory Biologics Linked to Reduced Asthma Exacerbations Across Patient Groups
4
SGLT2 Inhibitors Tied to Lower Platelet Activation in HFrEF
5